SLAS Discovery
Scope & Guideline
Shaping the Future of Biochemistry and Biotechnology
Introduction
Aims and Scopes
- High-Throughput Screening (HTS):
The journal extensively covers the development and optimization of high-throughput screening methodologies for drug discovery, enabling rapid evaluation of large compound libraries against biological targets. - Cell-Based Assays and Imaging:
SLAS Discovery emphasizes the use of cell-based assays, including high-content imaging and 3D cell cultures, to better mimic in vivo conditions and enhance the relevance of screening results. - Target Identification and Validation:
Research published in the journal often focuses on novel strategies for target identification and validation, including the application of proteomics and genomics to discover new drug targets. - Automation and Robotics in Drug Discovery:
The journal highlights advancements in automation and robotics that facilitate efficient assay development and compound screening, improving reproducibility and data quality in drug discovery. - Phenotypic Screening:
SLAS Discovery also explores phenotypic screening approaches that assess biological responses to compounds in cellular models, offering insights into complex drug action mechanisms. - Emerging Technologies:
The journal is dedicated to showcasing emerging technologies such as artificial intelligence (AI) and machine learning (ML) in drug discovery, aiming to enhance data analysis and predictive capabilities.
Trending and Emerging
- COVID-19 Therapeutics:
A significant number of recent publications are dedicated to discovering and validating therapeutics for COVID-19, reflecting the urgent need for effective treatments and the journal's responsiveness to global health challenges. - 3D Cell Culture and Organoids:
There is a growing trend towards the use of 3D cell culture systems and organoids, which provide more accurate representations of human tissues, enhancing drug screening and development processes. - Artificial Intelligence and Machine Learning:
The integration of AI and machine learning techniques into drug discovery processes is on the rise, with studies focusing on data mining, predictive modeling, and automated analysis to streamline hit identification. - Targeted Protein Degradation:
Research on targeted protein degradation, particularly using PROTACs (Proteolysis Targeting Chimeras), is emerging as a significant area of interest, offering new strategies for drug discovery against challenging targets. - Synergistic Drug Combinations:
There is an increasing focus on identifying synergistic drug combinations to enhance therapeutic efficacy, particularly in cancer treatment, which reflects a shift towards personalized medicine approaches.
Declining or Waning
- Traditional Biochemical Assays:
There is a noticeable decline in publications focusing solely on traditional biochemical assays, as the field moves towards more complex and physiologically relevant models. - Single-Dimensional Drug Screening:
Research centered around single-dimensional drug screening methods is waning, with a shift towards more integrated and multi-parametric approaches that provide a broader understanding of drug effects. - Basic Pharmacology Studies:
Basic pharmacology studies that do not incorporate advanced technologies or high-throughput capabilities appear to be less frequent, as there is a growing emphasis on translational research and clinical relevance. - In Vitro Models Lacking Complexity:
The use of simplistic in vitro models is decreasing, as researchers prioritize more complex systems that better replicate human physiology, such as organoids and multi-cellular models. - Focus on Established Targets:
There is a reduction in studies targeting well-characterized pathways or proteins, as the field increasingly seeks novel targets and mechanisms of action to overcome drug resistance.
Similar Journals
Current Bioinformatics
Empowering Discovery in Biochemistry and GeneticsCurrent Bioinformatics, an esteemed journal published by Bentham Science Publishers Ltd, serves as a pivotal platform for the dissemination of cutting-edge research in the fields of bioinformatics, biochemistry, computational mathematics, genetics, and molecular biology. With an ISSN of 1574-8936 and an E-ISSN of 2212-392X, this journal has established itself as a vital resource for researchers, professionals, and students keen on exploring interdisciplinary approaches to biological data analysis. Its prominence is reflected in its quartile rankings for 2023, where it stands in Q3 for biochemistry and computational mathematics, alongside Q4 rankings in genetics and molecular biology. Current Bioinformatics, located in the United Arab Emirates and converging from 2007 to 2024, aims to foster innovation in the field by presenting original research articles, reviews, and case studies that drive forward our understanding of complex biological systems through computational techniques. This journal is an integral resource for those wishing to stay at the forefront of bioinformatics research and applications.
CURRENT DRUG TARGETS
Elevating Drug Discovery to New HeightsCURRENT DRUG TARGETS is a leading peer-reviewed journal dedicated to advancements in the fields of Clinical Biochemistry, Drug Discovery, Molecular Medicine, and Pharmacology. Published by Bentham Science Publishers Ltd, this esteemed journal has solidified its position in the academic community with a 2023 Q2 ranking in several categories, highlighting its influence and relevance in drug research and development. With an ISSN of 1389-4501 and E-ISSN 1873-5592, CURRENT DRUG TARGETS facilitates the dissemination of high-quality articles that explore novel therapeutic strategies and drug design principles. Catered to researchers, professionals, and students, the journal has a commitment to advancing knowledge while addressing contemporary challenges in pharmacological sciences. As it converges from 2000 to 2024, CURRENT DRUG TARGETS remains a vital resource in understanding the complexities of drug action and interaction, making it indispensable for anyone pursuing cutting-edge research in related disciplines.
Letters in Drug Design & Discovery
Transforming Ideas into Breakthroughs in Drug DesignLetters in Drug Design & Discovery is an esteemed journal dedicated to advancing the fields of Drug Discovery and Molecular Medicine. Published by Bentham Science Publishers, this journal offers a platform for the dissemination of innovative research and advanced methodologies, enhancing collaboration among researchers and professionals in pharmaceutical sciences. Despite its current Q4 ranking in Drug Discovery and Molecular Medicine and Q3 in Pharmaceutical Science for 2023, the journal is committed to improving its presence in the academic community by providing quality, peer-reviewed publications that cover various aspects of drug design and discovery, including novel therapeutic approaches and methodologies. With a focus on both foundational and cutting-edge research from around the globe, Letters in Drug Design & Discovery is pivotal for those seeking to stay abreast of developments in drug development and molecular research. Researchers are encouraged to submit their work, engage with the burgeoning field, and contribute to the ongoing dialogue driven by this journal, which spans the years from 2005 to 2024. While the journal does not currently offer open access, its contributions remain accessible to a wide range of academic and professional audiences.
Journal of Cheminformatics
Elevating research standards in cheminformatics excellence.Journal of Cheminformatics, published by BMC, is a premier open-access journal that has been a cornerstone of cheminformatics research since its inception in 2009. With an ISSN of 1758-2946, this journal operates from the heart of the United Kingdom, providing a dynamic platform for disseminating high-quality, peer-reviewed articles that explore the integration of computer science with chemistry. The journal proudly stands in the prestigious Q1 category across multiple disciplines, including Computer Graphics, Computer-Aided Design, and Library and Information Sciences, showcasing its exceptional impact in the fields of cheminformatics and computational chemistry. Additionally, it ranks impressively in various Scopus categories, with notable placements such as #7 in Library and Information Sciences and #15 in Physical and Theoretical Chemistry, demonstrating its significance to the academic community. As a leader in open-access publishing, the Journal of Cheminformatics ensures that cutting-edge research and innovations are freely accessible to researchers, professionals, and students alike, fostering collaboration and advancement in this rapidly evolving field.
Current Computer-Aided Drug Design
Exploring New Horizons in Drug Design and Molecular MedicineCurrent Computer-Aided Drug Design, published by BENTHAM SCIENCE PUBL LTD, is a pivotal journal dedicated to the integration of computer-aided methodologies within the drug design process. With its ISSN 1573-4099 and E-ISSN 1875-6697, this journal serves as a vital resource for researchers, professionals, and students interested in advancing the fields of pharmacology and molecular medicine. Operating under a framework that spans from 2006 to 2024, it aims to foster innovative approaches and discussions surrounding drug design strategies, computational techniques, and the therapeutic potential of novel compounds. Although it currently holds a Q4 rating in Drug Discovery and Molecular Medicine as well as a Q3 in Medicine (miscellaneous) within the 2023 category quartiles, the journal continues to enhance its visibility and relevance in the academic community. Its Scopus rankings reflect its commitment to quality research, positioning it in the context of drug discovery and molecular studies. As the field of drug design evolves, Current Computer-Aided Drug Design remains an essential platform for disseminating cutting-edge findings and facilitating collaboration among specialists aiming for significant advancements in drug development.
JOURNAL OF BIOLOGICAL CHEMISTRY
Where Cutting-edge Research Meets Scientific RigorJOURNAL OF BIOLOGICAL CHEMISTRY, published by Elsevier, is a premier interdisciplinary journal dedicated to advancing our understanding of biochemistry, cell biology, and molecular biology. With a prestigious history dating back to 1945 and an impressive convergence of research expected to continue through 2024, this journal holds a Q1 ranking in all three of its core categories, signaling its critical influence in the respective fields, supported by a robust Scopus ranking that places it among the top echelons of internationally recognized research. Although currently not available as Open Access, the journal is essential for researchers and professionals looking to stay abreast of the latest breakthroughs and innovations in biochemical research. With a deep commitment to scientific rigor and a focus on diverse topics ranging from cellular processes to molecular mechanisms, the Journal of Biological Chemistry serves as a vital resource for the academic community, shaping the future of biological sciences.
Drug Metabolism and Pharmacokinetics
Unlocking the Secrets of Xenobiotic ProcessesDrug Metabolism and Pharmacokinetics is a premier academic journal committed to advancing the understanding of drug metabolism processes and pharmacokinetic principles critical to the development of therapeutics. Published by the Japanese Society for the Study of Xenobiotics, this journal has established itself as a vital resource within Pharmaceutical Science and Pharmacology, achieving a respectable Q2 ranking in the latest 2023 metrics. Spanning from 2002 to 2024, the journal publishes original research articles, reviews, and insights that address contemporary issues in xenobiotic metabolism and pharmacologic practices. With its ISSN of 1347-4367 and E-ISSN of 1880-0920, Drug Metabolism and Pharmacokinetics is indexed in leading databases, enhancing its visibility and accessibility for researchers, professionals, and students alike. By fostering a rigorous scientific dialogue, the journal plays an essential role in shaping the future of pharmacology and pharmaceutical sciences.
MedComm
Championing Transparency in Scientific PublishingMedComm is a distinguished Open Access journal published by Wiley, located in the United States. Since its inception in 2020, it has rapidly established itself as a leading platform for cutting-edge research in the fields of Biochemistry, Cell Biology, Drug Discovery, Genetics, Immunology and Allergy, and Oncology, achieving a prestigious Q1 category ranking across multiple disciplines in 2023. MedComm is committed to providing a rigorous and transparent peer-review process, ensuring the publication of high-quality articles that advance the frontiers of medical science. With its remarkable Scopus ranking, the journal serves as an invaluable resource for researchers, professionals, and students looking to stay abreast of important developments in the life sciences. The open access model facilitates widespread dissemination of scholarly work, fostering collaboration and innovation within the global scientific community. Researchers interested in submitting their work or exploring the latest findings are encouraged to engage with this pivotal journal during the converged years from 2020 to 2024.
Digital Discovery
Transforming Chemistry with Cutting-Edge Digital InsightsDigital Discovery is an innovative journal published by the Royal Society of Chemistry, specializing in the rapidly evolving field of digital chemistry and computational methods. Launched in 2022, this Open Access journal allows unrestricted access to cutting-edge research, which enhances the visibility and dissemination of scientific findings. With an impressive Q1 category ranking in Chemistry (miscellaneous) for 2023, Digital Discovery stands out as a pivotal platform for researchers looking to explore the intersections of digital innovation and chemical sciences. The journal is dedicated to publishing high-quality, peer-reviewed articles that push the boundaries of knowledge in this critical area of study, making it an essential resource for academics, industry professionals, and students alike. Readers can access all articles freely online, promoting a collaborative and inclusive academic community.
DRUG DISCOVERY TODAY
Your Gateway to Cutting-Edge Pharmaceutical ResearchDRUG DISCOVERY TODAY is a premier journal published by Elsevier Science Ltd, providing a vital platform for researchers, professionals, and students dedicated to the fields of drug discovery and pharmacology. With the ISSN 1359-6446 and E-ISSN 1878-5832, this esteemed journal has positioned itself at the forefront of scientific literature since its inception in 1996, boasting an impressive convergence set to last until 2024. Recognized for its rigorous peer-review process and high-quality publications, DRUG DISCOVERY TODAY attained a prestigious Q1 ranking in both Drug Discovery and Pharmacology categories for 2023, reflecting its significant impact and relevance in the field. With Scopus rankings placing it within the top percentile, at ranks #9 in Drug Discovery and #17 in Pharmacology out of over 300 journals, this journal serves as a crucial resource for the latest advancements and innovations in drug development. Although it does not offer Open Access, its comprehensive scope encompasses the most recent research, reviews, and insights, making DRUG DISCOVERY TODAY an essential read for anyone seeking to advance their knowledge and practice in pharmaceutical sciences.